Radioimmunotherapy
-
Subject Areas on Research
- A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
- An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy.
- Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
- Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
- Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
- Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
- Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
- Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
- Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
- Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy.
- Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
- Astatine-211: production and availability.
- Bilateral panocular involvement with mantle-cell lymphoma.
- Biokinetics of yttrium-90--labeled huBrE-3 monoclonal antibody.
- Chemotherapy and novel therapeutic approaches in malignant glioma.
- Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
- Clinical immunotherapy for brain tumors.
- Current status of therapy of solid tumors: brain tumor therapy.
- Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
- Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.
- Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
- Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
- Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
- Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.
- Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation.
- Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
- Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
- Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
- Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody.
- High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.
- High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
- Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
- Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.
- Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
- Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
- Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?
- Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
- Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.
- Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
- Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma.
- Non-Hodgkin's lymphomas, version 2.2014.
- Ocular adnexal lymphoma: monitoring response to therapy with diffusion-weighted imaging.
- Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.
- Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.
- Quantitative imaging of iodine-131 distributions in brain tumors with pinhole SPECT: a phantom study.
- Radioimmunotherapy for Non-Hodgkin's Lymphoma.
- Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
- Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
- Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
- Radioimmunotherapy with alpha-particle emitting radionuclides.
- Radioiodinated antibody targeting of the HER-2/neu oncoprotein.
- Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
- Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
- Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.
- Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
- Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
- Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
- Targeted radiotherapy of brain tumours.
- Targeted therapy using alpha emitters.
- Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
- Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
- Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.
- Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.
-
Keywords of People
- Reiman Jr., Robert Ellis, Associate Professor of Radiology, Radiology
- Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology